The Protein Degrader That Could Change How Late-Stage Myeloma Gets Treated
Multiple myeloma is one of the more stubborn blood cancers to treat. Patients often cycle...
The Protein Degrader That Could Change How Late-Stage Myeloma Gets Treated
70
Multiple myeloma is one of the more stubborn blood cancers to treat. Patients often cycle through several lines of therapy...
Standard BioTools Swaps Lab Gear for Cancer Drugs in Treeline Merger
128
For most of its existence, Standard BioTools Inc. (NASDAQ: LAB) built its business around the equipment side of life science...
LENZ Therapeutics Lands a New China Partner and an $85 Million Opportunity...
120
Presbyopia affects an estimated 1.8 billion people worldwide, yet for most of its history, the only practical solutions were reading...
Rett Syndrome Has No Approved Cure. Neurogene is Trying to Change That
146
Rett syndrome is a rare and severe neurological disorder that affects brain development, almost exclusively in girls. It typically appears...
Verastem Adds Another FDA Fast Track as it Targets a Hard to...
164
Verastem Oncology, Inc. (NASDAQ: VSTM) has added another regulatory milestone for VS 7375, a drug still in early testing but...
How a Blood Cancer Drug Trial Result Sent a Small-Cap Biotech Stock...
257
Biotech companies often face a defining moment when their most important clinical trial results arrive. This is especially true for...
Two Drugs, One Deadly Cancer and a New Collaboration Between a Small...
193
Pancreatic cancer has long been one of the most difficult cancers to treat. Survival rates remain grim, with only about...
Aveanna Healthcare Expands its Pediatric Care Network with a $175.5 Million All-Cash...
184
Home care is not a flashy corner of the healthcare industry, but it is becoming one of the more consequential...
Younger Drinkers Are Changing the Spirits Market
174
Younger adults are drinking less, and that change is starting to show up far beyond the cocktail glass. A 2025...
Three Hard-to-Treat Cancers, One Experimental Combination, and Remarkable Early Data
216
There is a particular reason that oncologists have long considered KRAS-mutated cancers to be among the most difficult to treat....
Three Times Longer Without a Seizure and Almost None of the Side...
214
Most people living with epilepsy are not just managing seizures. They are managing fatigue, mental fog, dizziness and drowsiness that...
New Cancer Drug Data Pushes Frontline Lung Cancer Treatment into a New...
193
Oncology drug development is entering a phase where the most interesting questions are not just about whether a therapy can...
Why the TrumpRx Expansion Could Change How Some Patients Shop for Prescriptions
216
The Trump administration has added more than 600 generic medicines to TrumpRx, its direct-to-consumer prescription website, and that change could...
Instil Bio’s Pivot from Setbacks to Strategic Partnerships
247
Instil Bio, Inc. (NASDAQ: TIL), a small-cap biotech based in Dallas, has always lived on two timelines. The first is...
How Data and Dollars Extend a Drug’s Journey
198
Hidradenitis suppurativa, or HS, affects about 1% of people worldwide, causing painful lumps, abscesses, and scarring in areas like the...
